Abbott Laboratories (ABT) Enterprise Value to EBITDA (EV/EBITDA): 16.41

Since December 31st, 2007, Abbott Laboratories's enterprise value to ebitda (ev/ebitda) has increased from 5.95 to 16.41 at May 24th, 2022.

From 2007 to 2022 Abbott Laboratories's highest enterprise value to ebitda (ev/ebitda) was 28.18
Abbott Laboratories's lowest enterprise value to ebitda (ev/ebitda) during that period was 3.53
Abbott Laboratories's average enterprise value to ebitda (ev/ebitda) from 2007 to 2022 Abbott Laboratories's was 13.77

Abbott Laboratories's enterprise value to ebitda (ev/ebitda) as of May 24th, 2022 of 16.41 was lower than its peers in the Medical Appliances & Equipment industry group of April 30th, 2022 of 115,807.76. From December 31st, 2007 to May 24th, 2022, Abbott Laboratories's average enterprise value to ebitda (ev/ebitda) was 13.77 compared to an industry average of 3,374.09.

About Abbott Laboratories

Abbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure and other medical device products. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.